RU2018126399A3 - - Google Patents

Info

Publication number: RU2018126399A3
Authority: RU; Russia

Application number

RU2018126399A

Other versions

RU2018126399A (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-14

Filing date

2017-01-13

Publication date

2020-06-09

2017-01-13 Application filed filed Critical

2020-02-14 Publication of RU2018126399A publication Critical patent/RU2018126399A/ru

2020-06-09 Publication of RU2018126399A3 publication Critical patent/RU2018126399A3/ru

2021-12-02 Application granted granted Critical

2021-12-02 Publication of RU2760997C2 publication Critical patent/RU2760997C2/ru

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Biophysics (AREA)
Toxicology (AREA)
General Engineering & Computer Science (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

RU2018126399A 2016-01-14 2017-01-13 Композиции и способы для лечения диабета 1 типа RU2760997C2 (ru)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201662278493P	2016-01-14	2016-01-14
US62/278,493		2016-01-14
US201662350472P	2016-06-15	2016-06-15
US62/350,472		2016-06-15
PCT/IB2017/050204 WO2017122180A1 (en)	2016-01-14	2017-01-13	Compositions and methods for the treatment of type 1 diabetes

Publications (3)

Publication Number	Publication Date
RU2018126399A RU2018126399A (ru)	2020-02-14
RU2018126399A3 true RU2018126399A3 (ru)	2020-06-09
RU2760997C2 RU2760997C2 (ru)	2021-12-02

Family

ID=57960562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2018126399A RU2760997C2 (ru)	2016-01-14	2017-01-13	Композиции и способы для лечения диабета 1 типа

Country Status (9)

Country	Link
US (3)	US10905727B2 (ru)
EP (2)	EP3402499B1 (ru)
JP (3)	JP7292877B2 (ru)
CN (1)	CN108883140A (ru)
AU (2)	AU2017208153B2 (ru)
CA (1)	CA3011331A1 (ru)
DK (1)	DK3402499T3 (ru)
RU (1)	RU2760997C2 (ru)
WO (1)	WO2017122180A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6175428B2 (ja)	2011-06-01	2017-08-02	イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎＡｃｔｏｂｉｏｔｉｃｓＮＶ	細菌のポリシストロン性発現系
RU2760997C2 (ru) *	2016-01-14	2021-12-02	Интрексон Актобиотикс Н.В.	Композиции и способы для лечения диабета 1 типа
CN107028985A (zh) *	2016-02-04	2017-08-11	深圳华大基因研究院	厚壁菌类益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
KR102469701B1 (ko)	2016-09-13	2022-11-22	인트랙슨 액토바이오틱스 엔.브이.	점막부착성 미생물
WO2018170288A1 (en)	2017-03-15	2018-09-20	Pandion Therapeutics, Inc.	Targeted immunotolerance
CA3064435A1 (en)	2017-05-24	2018-11-29	Pandion Therapeutics, Inc.	Targeted immunotolerance
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
USRE50550E1 (en)	2017-12-06	2025-08-26	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174091B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
GB201805329D0 (en)	2018-03-30	2018-05-16	Univ Leuven Kath	Biomakers for diabetes therapy
CN113166241B (zh)	2018-08-16	2025-02-25	约翰霍普金斯大学	人类znt8抗体
KR20230031981A (ko)	2019-05-14	2023-03-07	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN114679909A (zh)	2019-05-20	2022-06-28	潘迪恩运营公司	MAdCAM靶向的免疫耐受
CN110184214B (zh) *	2019-05-21	2022-07-01	黑龙江大学	一种开菲尔乳杆菌及其菌制剂
CN110144311B (zh) *	2019-05-21	2022-07-01	黑龙江大学	一种开菲尔乳杆菌及其菌制剂
CA3140507A1 (en) *	2019-05-31	2020-12-03	Universitat Autonoma De Barcelona	Insulin gene therapy
US12366570B2 (en)	2019-10-01	2025-07-22	The Johns Hopkins University	Cell-based ZNT8 assay
JP7362417B2 (ja) *	2019-10-25	2023-10-17	ライオン株式会社	口腔内病原性細菌の生育抑制剤、口腔用組成物及び促進剤
EP4107187A4 (en)	2020-02-21	2024-07-03	Pandion Operations, Inc.	TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
AU2021287998A1 (en)	2020-06-11	2023-02-02	Benaroya Research Institute At Virginia Mason	Methods and compositions for preventing type 1 diabetes
JP2023544832A (ja) *	2020-10-08	2023-10-25	ドクターメアリーモリスアンドアソシエイツリミテッドライアビリティカンパニー	１型糖尿病の治療および予防のための方法および組成物
TWI777475B (zh) *	2021-03-30	2022-09-11	豐華生物科技股份有限公司	使用乳酸菌菌株組合來治療第1型糖尿病
CN114042091A (zh) *	2021-10-24	2022-02-15	郑州大学	酪黄肠球菌在制备治疗代谢综合征产品中的应用方法
CN114377117B (zh) *	2021-12-06	2023-11-10	中国医学科学院医学生物学研究所	一种口服1型糖尿病疫苗及其制备方法
CN114561318B (zh) *	2021-12-29	2022-11-08	云南农业大学	一株鼠乳杆菌及其在治疗ii型糖尿病中的应用
WO2023229282A1 (ko) *	2022-05-25	2023-11-30	전남대학교산학협력단	락토바실러스 쿤케이 nchbl-003 균주 또는 이의 배양액을 포함하는 대사성 질환 예방, 치료 또는 개선용 조성물
CN118834876B (zh) *	2024-08-21	2025-03-21	迪辅乐生物(上海)有限公司	一种乳酸菌组成型启动子、重组载体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB227835A (en)	1924-01-15	1925-04-09	Harry Odell	Improvements in feeding mechanism for embossing and other printing presses
JPS58116498A (ja)	1981-12-28	1983-07-11	Takeda Chem Ind Ltd	Ｉｌ‐２をコードする新規伝令ｒｎａの製造法
EP0091539B2 (en)	1982-03-31	1996-11-27	Ajinomoto Co., Inc.	Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
US4752585A (en)	1985-12-17	1988-06-21	Cetus Corporation	Oxidation-resistant muteins
US4919918A (en)	1988-03-14	1990-04-24	Spectrum Consumer Products Co., Inc.	Non-alcoholic mouthwash
US5972685A (en)	1988-07-21	1999-10-26	Iowa State University Research Foundation, Inc.	Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
GB9006400D0 (en)	1990-03-22	1990-05-23	Ciba Geigy Ag	Bacterial vectors
US6221840B1 (en)	1991-02-14	2001-04-24	The General Hospital Corporation	Intestinal trefoil proteins
AU1415892A (en)	1991-02-14	1992-09-15	General Hospital Corporation, The	Intestinal trefoil proteins
US6277969B1 (en)	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9126306D0 (en)	1991-12-11	1992-02-12	Unilever Plc	Mouthwash compositions
CA2130453A1 (en)	1992-02-27	1993-09-02	Richard W. F. Le Page	Heterologous gene expression in lactococcus, and the expression products threrefrom
US5223285A (en)	1992-03-31	1993-06-29	Abbott Laboratories	Nutritional product for pulmonary patients
EP0569604A1 (en)	1992-04-07	1993-11-18	Societe Des Produits Nestle S.A.	Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
US5700782A (en)	1993-05-28	1997-12-23	Abbott Laboratories	Enteral nutritional product
WO1996032486A1 (en)	1995-04-11	1996-10-17	Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno	Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5695746A (en)	1995-07-28	1997-12-09	Chesebrough-Pond's Usa Co., Division Of Conopco, Inc.	Liquid dentifrice with mouthwash fresh taste
GB9521568D0 (en)	1995-10-20	1995-12-20	Lynxvale Ltd	Delivery of biologically active polypeptides
WO1997026855A1 (en)	1996-01-24	1997-07-31	Warner-Lambert Company	Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
GB9611364D0 (en)	1996-05-31	1996-08-07	Smithkline Beecham Plc	Composition
JP3895388B2 (ja)	1996-09-18	2007-03-22	ジョハンセン，アーリング	過飽和溶液中のカルシウムおよびリン酸イオンからなるうがい薬
US5869118A (en)	1996-11-13	1999-02-09	Abbott Laboratories	Gellan gum to improve physical stability of liquid nutritional products
US6171611B1 (en)	1997-11-12	2001-01-09	Dante J. Picciano	Iodine-containing nasal moisturizing saline and mouthwash solutions
US5897872A (en)	1997-11-12	1999-04-27	Picciano; Dante J.	Iodine-containing nasal moisturizing saline solution
ID28275A (id)	1998-09-28	2001-05-10	Warner Lambert Co	Penghantaran kolon dan enterik yang menggunakan kapsul-kapsul hpmc
AU1071200A (en)	1998-10-19	2000-05-08	Biotech Australia Pty Limited	Systems for oral delivery
AU770726B2 (en)	1998-10-20	2004-02-26	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Use of a cytokine-producing lactococcus strain to treat colitis
ATE274060T1 (de)	1999-06-30	2004-09-15	Nestle Sa	Das lactobacillus delbrueckii lactose operon und deren verwendung zur kontrolle der transkription und/oder expression von gene in bakterienzellen
PT1194554E (pt)	1999-07-05	2007-01-31	Vlaams Interuniv Inst Biotech	Libertação de péptidos trifólios
AU2001238582A1 (en)	2000-02-24	2001-09-03	Siga Pharmaceuticals, Inc	Intergenic and intragenic integration sites for foreign gene expression in recombinant s. gordonii strains
US7029842B2 (en)	2000-04-07	2006-04-18	Novozymes A/S	Signal sequence trapping
GB0013810D0 (en)	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
EP1383897B1 (en)	2001-05-03	2006-06-28	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Self-containing lactococcus strain
MXPA05001520A (es)	2002-07-08	2005-05-05	Joe S Wilkins Jr	Formulaciones antibacteriales.
AU2003298291A1 (en)	2002-11-15	2004-06-15	Universiteit Gent	Self-containing lactobacillus strain
WO2004069177A2 (en)	2003-01-31	2004-08-19	The Trustees Of The University Of Pennsylvania	Methods for modulating an inflammatory response
EP1493816A1 (en)	2003-07-02	2005-01-05	Friesland Brands B.V.	Methods and means for regulating gene expression
WO2005007121A2 (en)	2003-07-18	2005-01-27	Massachusetts Institute Of Technology	Mutant interleukin-2(il-2) polypeptides
WO2005071088A2 (en)	2003-12-24	2005-08-04	Cerus Corporation	Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
US20060234205A1 (en)	2004-03-05	2006-10-19	Chiron Corporation	In vitro test system for predicting patient tolerability of therapeutic agents
ITRM20050398A1 (it) *	2005-07-26	2007-01-27	Gian Franco Bottazzo	Metodo per la rilevazione di cellule t in pazienti neodiagnosticati per diabete di tipo 1.
CN101426532A (zh) *	2005-12-08	2009-05-06	路易斯维尔大学研究基金会有限公司	体内细胞表面工程化
WO2008084115A2 (en)	2007-01-12	2008-07-17	Actogenix N.V.	Lactococcus promoters and uses thereof
DK3181682T3 (da) *	2008-09-29	2021-07-05	Intrexon Actobiotics Nv	Reduceret kolonisering af mikrober på slimhinden
US9574169B2 (en)	2009-04-30	2017-02-21	Intrexon Actobiotics Nv	Cryoprotectants for freeze drying of lactic acid bacteria
US20130164380A1 (en)	2010-06-17	2013-06-27	Actogenix Nv	Compositions and methods for treating inflammatory conditions
PL3075745T3 (pl)	2011-02-10	2019-07-31	Roche Glycart Ag	Zmutowane polipeptydy interleukiny-2
ES2811624T3 (es) *	2011-03-11	2021-03-12	Hopitaux Paris Assist Publique	Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
JP6175428B2 (ja)	2011-06-01	2017-08-02	イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎＡｃｔｏｂｉｏｔｉｃｓＮＶ	細菌のポリシストロン性発現系
CA2847555A1 (en) *	2011-09-08	2013-03-14	University Of Florida Research Foundation, Inc.	Materials and methods for modulating immune responses
RU2653757C2 (ru) *	2011-09-23	2018-05-14	Интрексон Актобиотикс Н.В.	Модифицированные грамположительные бактерии и их применение
CN104413334A (zh) *	2013-08-30	2015-03-18	深圳华大基因科技有限公司	可食用组合物及其制备方法和用途
EA201992609A1 (ru)	2014-02-06	2020-03-04	Ф.Хоффманн-Ля Рош Аг	Слитые белки, содержащие интерлейкин-2, и их применения
RU2760997C2 (ru) *	2016-01-14	2021-12-02	Интрексон Актобиотикс Н.В.	Композиции и способы для лечения диабета 1 типа

2017
- 2017-01-13 RU RU2018126399A patent/RU2760997C2/ru active
- 2017-01-13 EP EP17702950.1A patent/EP3402499B1/en active Active
- 2017-01-13 JP JP2018536741A patent/JP7292877B2/ja active Active
- 2017-01-13 US US16/069,947 patent/US10905727B2/en active Active
- 2017-01-13 AU AU2017208153A patent/AU2017208153B2/en not_active Ceased
- 2017-01-13 WO PCT/IB2017/050204 patent/WO2017122180A1/en not_active Ceased
- 2017-01-13 DK DK17702950.1T patent/DK3402499T3/da active
- 2017-01-13 CA CA3011331A patent/CA3011331A1/en active Pending
- 2017-01-13 EP EP21185734.7A patent/EP3919065B9/en active Active
- 2017-01-13 CN CN201780011344.4A patent/CN108883140A/zh active Pending
2021
- 2021-01-15 US US17/150,352 patent/US11786567B2/en active Active
- 2021-04-27 AU AU2021202600A patent/AU2021202600B2/en not_active Ceased
- 2021-08-30 JP JP2021139503A patent/JP2022023025A/ja not_active Withdrawn
2023
- 2023-08-18 JP JP2023133189A patent/JP2023166421A/ja active Pending
- 2023-09-08 US US18/463,461 patent/US12246046B2/en active Active

Also Published As

Publication number	Publication date
EP3919065A9 (en)	2023-08-02
CN108883140A (zh)	2018-11-23
EP3919065B9 (en)	2024-01-24
US12246046B2 (en)	2025-03-11
JP7292877B2 (ja)	2023-06-19
AU2017208153B2 (en)	2021-01-28
EP3919065B1 (en)	2023-11-08
US11786567B2 (en)	2023-10-17
AU2021202600B2 (en)	2023-11-02
AU2021202600A1 (en)	2021-05-27
US10905727B2 (en)	2021-02-02
EP3919065A1 (en)	2021-12-08
JP2023166421A (ja)	2023-11-21
JP2022023025A (ja)	2022-02-07
AU2017208153A1 (en)	2018-08-09
EP3402499B1 (en)	2021-07-21
WO2017122180A1 (en)	2017-07-20
CA3011331A1 (en)	2017-07-20
US20190022154A1 (en)	2019-01-24
US20210154247A1 (en)	2021-05-27
RU2018126399A (ru)	2020-02-14
DK3402499T3 (da)	2021-09-27
JP2019505524A (ja)	2019-02-28
EP3402499A1 (en)	2018-11-21
US20240082323A1 (en)	2024-03-14
RU2760997C2 (ru)	2021-12-02

Publication	Publication Date	Title
BR112019009389A2 (ru)	2019-07-23
RU2018126399A3 (ru)	2020-06-09
BR122021013712A2 (ru)	2019-11-19
BR122020022459A2 (ru)	2019-06-25
BR112019009192A2 (ru)	2019-07-23
BR112019006736A2 (ru)	2019-07-23
BR202016025584U2 (ru)	2018-05-29
BR202016021516U2 (ru)	2018-04-03
CN303539243S (ru)	2016-01-06
CN303539080S (ru)	2016-01-06
CN303652984S (ru)	2016-04-27
CN303652166S (ru)	2016-04-27
CN303628642S (ru)	2016-03-30
CN303615268S (ru)	2016-03-16
CN303613455S (ru)	2016-03-09
CN303595887S (ru)	2016-02-24
CN303594858S (ru)	2016-02-24
CN303592121S (ru)	2016-02-17
CN303582414S (ru)	2016-02-10
CN303572344S (ru)	2016-01-27
CN303564324S (ru)	2016-01-20
CN303553979S (ru)	2016-01-20
CN303551202S (ru)	2016-01-13
CN303549527S (ru)	2016-01-13
CN303658387S (ru)	2016-05-04